TCGA-67-6216-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.390
- ALLOGRAFT_REJECTION+0.370
- INTERFERON_ALPHA_RESPONSE+0.370
- INFLAMMATORY_RESPONSE+0.340
- COAGULATION+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.270
- COMPLEMENT+0.260
- P53_PATHWAY+0.250
- APOPTOSIS+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.540
- E2F_TARGETS-0.510
- MYC_TARGETS_V2-0.480
- MYC_TARGETS_V1-0.400
- MTORC1_SIGNALING-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- SPERMATOGENESIS-0.320
- OXIDATIVE_PHOSPHORYLATION-0.250
- MITOTIC_SPINDLE-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-4505-01A-01R-1206-07 | — | cohortA1 | 0.865 |
| 2 | TCGA-95-8039-01A-11R-2241-07 | — | cohortA1 | 0.864 |
| 3 | SRR8943004 | — | — | 0.862 |
| 4 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.861 |
| 5 | SRR8518288 | — | A | 0.858 |
| 6 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.855 |
| 7 | BS_KN92S7YQ | Med | Medulloblastoma | 0.855 |
| 8 | R232 | — | — | 0.854 |
| 9 | TCGA-OR-A5LK-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Oncocytic Type | 0.853 |
| 10 | MDT-AP-2283 | Med | Medulloblastoma | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |